New Products: Once-a-month Actonel option approved

Article

Once monthly dose of Actonel has been approved to treating and preventing postmenopausal osteoporosis.

The Agency okayed the new dosage on the basis of a study of 642 women that compared 150 mg of Actonel monthly to 5 mg daily of the tablet. The study showed similar increases for both groups in lumbar spine bone mineral density and at other sites from baseline at 1 year. Produced by Procter and Gamble Pharmaceuticals, the drug is marketed by Sanofi-Aventis U.S. For more information on Actonel, visit the Web site at http://www.actonel.com/.

Related Videos
Shocking maternal health findings from 2023 March of Dimes report card | Image Credit: marchofdimes.org
The importance of maternal vaccination | Image Credit: nfid.org.
Expert on OAB
Expert on OAB
How to address sexual dysfunction during menopause | Image Credit: health.usnews.com
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
Experts on OAB
Expert on OAB
Expert on OAB
© 2023 MJH Life Sciences

All rights reserved.